Taltobulin

Taltobulin (HTI-286), a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Taltobulin inhibits the polymerization of purified tubulin, disrupts microtubule organization in cells, and induces mitotic arrest, as well as apoptosis[1].

Product Specifications

CAS Number

[228266-40-8]

Product Name Alternative

HTI-286; SPA-110

UNSPSC

12352203

Hazard Statement

H302, H315, H319, H335

Target

ADC Payload; Apoptosis; Microtubule/Tubulin

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related; Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/taltobulin.html

Purity

99.90

Solubility

DMSO : ≥ 100 mg/mL

Smiles

CC(C)(C)[C@H](NC([C@H](C(C)(C1=CC=CC=C1)C)NC)=O)C(N([C@@H](C(C)C)/C=C(C(O)=O)\C)C)=O

Molecular Formula

C27H43N3O4

Molecular Weight

473.65

Precautions

H302, H315, H319, H335

References & Citations

[1]Loganzo F, et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res. 2003 Apr 15;63 (8) :1838-45.